CLINICAL TRIALS PROFILE FOR SYLVANT
✉ Email this page to a colleague
All Clinical Trials for SYLVANT
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02641522 ↗ | Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes | Completed | Janssen Research & Development, LLC | Early Phase 1 | 2016-03-08 | The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D). |
NCT02641522 ↗ | Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes | Completed | Carla Greembaum, MD | Early Phase 1 | 2016-03-08 | The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D). |
NCT02641522 ↗ | Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes | Completed | Carla Greenbaum, MD | Early Phase 1 | 2016-03-08 | The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SYLVANT
Condition Name
Clinical Trial Locations for SYLVANT
Trials by Country
Clinical Trial Progress for SYLVANT
Clinical Trial Phase
Clinical Trial Sponsors for SYLVANT
Sponsor Name